Evidence map›Paper›PMID 22427742›Full record

ArticlePLoS biology2012

Convergent evolution of escape from hepaciviral antagonism in primates.

Maulik R Patel, Yueh-Ming Loo, Stacy M Horner, Michael Gale, Harmit S Malik

Open access · goldAbstract read
In one paragraph

Article in PLoS biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 97 citations in OpenAlex.

  1. Review
  2. Article
  3. Conserved Functions ofInternational journal of molecular sciences · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Maulik R PatelDivision of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Yueh-Ming Loo
Stacy M Horner
Michael Gale
Harmit S Malik
University of Washington · USFred Hutch Cancer Center · USHoward Hughes Medical Institute · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Thomas James Lynch · 1985 to 2026
$296.4M
West Nile Virus and host control of innate defensesU19AI083019 · NIAID · UNIVERSITY OF WASHINGTON · PI CLARK, EDWARD A · 2009 to 2018
$22.5M
Mechanisms Of Pathogen Recognition And Innate Immune Control Of Hepatitis C VirusU19AI088778 · NIAID · UNIVERSITY OF WASHINGTON · PI GALE, MICHAEL · 2010 to 2014
$4.2M
The Host Response to Hepatitis C VirusR01AI060389 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI GALE, MICHAEL · 2003 to 2012
$3.4M
The Host Response to Hepatitis C VirusR56AI060389 · NIAID · UNIVERSITY OF WASHINGTON · PI GALE, MICHAEL · 2014 to 2014
$494k
Howard Hughes Medical InstituteNCI NIH HHS P30 CA015704NIAID NIH HHS AI060389NIAID NIH HHS AI083019NIAID NIH HHS AI88778NIAID NIH HHS R01 AI060389NIAID NIH HHS R56 AI060389NIAID NIH HHS U19 AI083019NIAID NIH HHS U19 AI088778
6 · The paper itself

Abstract

The ability to mount an interferon response on sensing viral infection is a critical component of mammalian innate immunity. Several viruses directly antagonize viral sensing pathways to block activation of the host immune response. Here, we show that recurrent viral antagonism has shaped the evolution of the host protein MAVS--a crucial component of the viral-sensing pathway in primates. From sequencing and phylogenetic analyses of MAVS from 21 simian primates, we found that MAVS has evolved under strong positive selection. We focused on how this positive selection has shaped MAVS' susceptibility to Hepatitis C virus (HCV). We functionally tested MAVS proteins from diverse primate species for their ability to resist antagonism by HCV, which uses its protease NS3/4A to cleave human MAVS. We found that MAVS from multiple primates are resistant to inhibition by the HCV protease. This resistance maps to single changes within the protease cleavage site in MAVS, which protect MAVS from getting cleaved by the HCV protease. Remarkably, most of these changes have been independently acquired at a single residue 506 that evolved under positive selection. We show that "escape" mutations lower affinity of the NS3 protease for MAVS and allow it to better restrict HCV replication. We further show that NS3 proteases from all other primate hepaciviruses, including the highly divergent GBV-A and GBV-C viruses, are functionally similar to HCV. We conclude that convergent evolution at residue 506 in multiple primates has resulted in escape from antagonism by hepaciviruses. Our study provides a model whereby insights into the ancient history of viral infections in primates can be gained using extant host and virus genes. Our analyses also provide a means by which primates might clear infections by extant hepaciviruses like HCV.

Indexed as

Evolution, MolecularAdaptor Proteins, Signal TransducingAmino Acid SequenceAnimalsDEAD-box RNA HelicasesGenes, ViralHepacivirusHepatitis CHost-Pathogen InteractionsHumansModels, MolecularMolecular Sequence DataNucleoside-TriphosphatasePhylogenyPrimatesProteolysisAdaptor Proteins, Signal TransducingDEAD-box RNA HelicasesNS3 protein, hepatitis C virusNucleoside-TriphosphataseSerine EndopeptidasesViral Nonstructural ProteinsViral Proteases

Identifiers

PMID22427742
PMCPMC3302847
OpenAlexW2120167579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.